| INTRODUC TI ON
The incidence of melanoma continues to rise at a faster rate than all other solid tumors (Erdmann et al., 2013) . Among metastatic melanoma patients, the majority have a BRAF V600E mutation that induces oncogenic BRAF kinase activity and leads to enhanced survival and proliferation of melanoma cells (Hodis et al., 2012; Holmes, 2014) . Despite the promising initial response of patients treated with inhibitors that target the oncogenic BRAF V600E mutation, most patients' tumors eventually develop resistance to these treatments (Van Allen et al., 2014; Wagle et al., 2011) . Furthermore, a combined immunotherapy that targets PD-1 and CTLA-4 improves outcome, but only a fraction of patients obtain clinical benefit and this treatment has important side effects (Hamid et al., 2013; Hodi et al., 2010; Johnson, Balko et al., 2016; Phan et al., 2003) .
Given the high rate of mutation and a broad range of genomic alterations observed after therapy in melanoma, cell diversity or intratumor cellular heterogeneity has also been implicated as a cellular mechanism of therapy escape (Johnson et al., 2017; Van Allen et al., 2014) .
Study of melanoma and other solid tumors has increasingly moved toward approaches that monitor the collection of cell types within tients' tumors could identify malignant or immunologic cell types that may predict treatment response or resistance (Johnson, Estrada et al., 2016) . Only recently have studies begun to perform single-cell analysis on matched tumors from patients before and after therapy (Hugo et al., 2015; Tirosh et al., 2016) . These single-cell studies have focused on RNA expression and use measurements of selected proteins as a confirmation tool. Pairing longitudinal studies with single-cell analysis of proteins involved in melanoma cell identity and function could lead to a better understanding of the evolution of resistance and therapy evasion (Irish, 2014; Meacham & Morrison, 2013) .
Technological advances have led to the development of several platforms made to dissect cell diversity. Single-cell genomic approaches enable a detailed evaluation of genomic and transcriptional features of cancer cells (Patel et al., 2014; Tirosh et al., 2016) . While studies that utilize transcriptional profiling have identified resistant cells in relapsed tumors, these results do not align to identify a common resistant cell phenotype (Hugo et al., 2015; Tirosh et al., 2016) . Furthermore, discrepancies between mRNA and protein expression indicate not all transcripts are regulated in a way that leads to detectable levels of protein (Koussounadis, Langdon, Um, Harrison, & Smith, 2015; Zhang et al., 2014) . Mass cytometry uses metal-labeled antibodies detected using time-of-flight mass spectrometry, permitting detection of more than 30 proteins per cell (Bendall et al., 2011; Bjornson, Nolan, & Fantl, 2013) . The use of metal-labeled, rather than fluorophore-labeled, antibody tags significantly reduces issues with spectral overlap and cell autofluorescence (Leelatian, Doxie, Greenplate, Mobley et al., 2017; Nicholas et al., 2016) . Due to these advantages, mass cytometry has gained acceptance for the study of solid tissues (Wang et al., 2016; Wogsland et al., 2017) . More recently, standardized methods have been developed to create viable single-cell suspensions from solid tumors and tissues .
This study introduces the application of mass cytometry to characterize the cell diversity of human melanoma tumors by measuring 32 proteins simultaneously before and during ongoing targeted therapy from the same tumor sites. This work aims to characterize and track changes to cancer cell phenotypes that appear during combination BRAF V600E and MEK inhibition. By simultaneously measuring several proteins in tens of thousands of cells, mass cytometry could reveal novel features defining subsets that may be used for future therapeutic development (Irish, 2014; Spitzer & Nolan, 2016) .
In an ideal manner, by revealing new cell types and their signature features, a single-cell systems biology approach might both provide ways to track heterogeneous melanoma cell subsets and discover new hypotheses for cellular mechanisms of resistance.
| MATERIAL S AND ME THODS

| Cell culture and cell lines
MeWo, A2058, WM115, and SKMEL28 cells were grown in Minimum
Essential Medium (Mediatech, Inc., Manassas, VA), supplemented with 10% fetal bovine serum (Gibco standard FBS, Life Technologies, Grand Island, NY), 1% penicillin (Gibco), and 1% streptomycin (Gibco).
Jurkat T cells were grown in RPMI (Mediatech, Inc., Manassas, VA)
supplemented with 10% fetal bovine serum (Gibco standard FBS, Life Technologies, Grand Island, NY), 1% penicillin (Gibco), and 1% streptomycin (Gibco). All cell lines were acquired as gifts from the laboratory of Dr. Vito Quaranta.
| Tumor collection and dissociation
Lymph nodes and subcutaneous tumors from adults with metastatic melanoma were biopsied or surgically resected from 15 individual patients in accordance with the Declaration of Helsinki. Institutional ethics approval was obtained from the Vanderbilt Institutional
Review Board (project numbers 121165 and 030220). All patients had provided written informed consent prior to inclusion in the study. All patients in this study presented with either several subcutaneous legions or distal metastasis. All tumors within the study were thought to arise as cutaneous legions because no evidence of disease was present in mucosal epithelium or retinas. 11 patients received 2 weeks of BRAF V600E inhibitor dabrafenib followed by 2 weeks of dabrafenib and MEK inhibitor trametinib (Supporting information Table S1 and (Johnson, Crandall, Dahlman, & Kelley, 2015) ). Pretreatment (Pre-Tx) tumors were naïve to BRAF V600E inhibitor dabrafenib MEK inhibitor trametinib. More details of patients from this clinical study can be found with clinical trial code NCT01701037. Core biopsies were obtained before therapy, and remaining tumors were surgically resected after 4 weeks of therapy.
Tumor samples were enzymatically digested into a single-cell suspension and cryopreserved with techniques developed specifically to isolate viable melanoma tumor cells (Leelatian, Doxie, Greenplate, Mobely et al., 2017; 
| Tissue microarrays and immunohistochemistry
Melanoma tumors from the study were prepared and processed into TMAs by the VUMC Translational Pathology Shared Resource (TPSR) (Supporting information 
| Fluorescence flow cytometry
Lives cells from patient 001 (MP-001) and Jurkat T cells were
stained with fluorescent antibodies to analyze signaling status.
Before stimulating cells for signaling, Alexa fluorophore 700
(Thermo Fisher Scientific, Waltham, MA) was added, as previously described (Irish & Doxie, 2014; Leelatian, Doxie, Greenplate, Mobely et al., 2017) . Alexa fluorophores can be used to test membrane permeability as a way to exclude dead and dying cells (Irish & Doxie, 2014; Krutzik & Nolan, 2006 
| Mass cytometry
Live cells from tumors obtained from the same dissociation conditions as fluorescence flow cytometry analysis were stained for cell surface markers, fixed, permeabilized, and washed in concordance with established dissociation and mass cytometry protocols (Leelatian et al., 2015; Table S2 ). After staining, cells were washed once with PBS, once with deionized water, pelleted at 800× g, resuspended in deionized water, and collected using a CyTOF 1 (Fluidigm) mass cytometer.
| Data analysis
Cytobank was used to store.fcs files and perform data analysis including viSNE gating of major tumor cell populations (Amir El et al., 2013; Kotecha, Krutzik, & Irish, 2010) . Statistical analysis of cells gated from samples before and after therapy was performed using commercial 2D graphing and statistics software GraphPad Prism. 
| Single-cell analysis of human melanoma tumors
Viable nucleated cells were gated with total histone H3 and rhodium Table S2 ). Major populations of cells were identified and quantified using expert gating performed on patient-specific viSNE maps of the pretherapy-post-therapy tumors. (Supporting information Table S3 ).
To study how cellular heterogeneity was affected by therapy, cells were placed into a workflow that emphasized unsupervised subset identification, characterization, and data visualization with FlowSOM, MEM, and viSNE analysis (Diggins, Ferrell, & Irish, 2015; Diggins et al., 2017 Diggins et al., , 2018 Van Gassen et al., 2015) . To identify subsets enriched before and after therapy, the viSNE analysis was performed using 17 markers with a variance greater than 0.2 (Supporting information Table S2 ). FlowSOM cluster analysis was conducted using t-SNE axes as inputs for clustering.
Additional patients' melanoma cells included in Figure 4 were gated as CD45 negative. Cells from these patients were analyzed using shared markers from the optimized melanoma mass cytometry panel (MP-004, MP-012, MP-019, MP-022, MP-023, MP-040, and MP-054) (Supporting information Table S2 ).
| Statistics
Nonparametric Kolmogorov-Smirnov tests with a significance threshold of p = 0.05 were used to compare differences in median mass intensity in Figure 
| Data availability
Mass cytometry data for this manuscript can be accessed via 
MP-059 Pre-Tx tumor cell population #7), which indicted these cells were relatively enriched for B lineage CD19 and leukocyte CD45
proteins and specifically lacking melanoma cell proteins, including S100β, SOX10, and MCAM ( Figure 1b ). This computational workflow using viSNE and MEM reduces bias that can arise in manual gating and characterizes phenotypically unusual cells that may be overlooked or hidden in traditional analyses (Diggins et al., , 2017 Irish, 2014) .
From the protein expression and cellular abundance data in the viSNE and MEM analysis, cells were classified into one of the five major groups (Supporting information Table S3 ). The most abundant stromal populations were defined as follows: (a) in Phase II interventional study NCT01701037 were obtained as a biopsy prior to neoadjuvant therapy (Pre-Tx) using dabrafenib and trametinib therapy or from surgical resection after 4 weeks of therapy (Week 4). Viable single cells were isolated following established protocols (Leelatian et al., 2016; , analyzed by mass cytometry, and characterized using a modular, unsupervised computational workflow created for melanoma from dimensionality reduction tool t-SNE/viSNE (Amir El et al., 2013) , clustering tool FlowSOM (Van Gassen et al., 2015) , and cell subset identification and protein enrichment characterization with MEM (Diggins et al., 2017) . In (b), viSNE plots and MEM labels used to identify and characterize cells from melanoma tumors are shown. viSNE plots display all live cells from one Pre-Tx melanoma tumor (MP-059) arranged according to protein expression and shaded based on cell type (B, left) or abundance (B, middle, density plot). MEM labels quantified protein enrichment (▲ up to +10) or specific absence (▼ down to -10) in the indicated tumor cell subset. For example, melanoma cells in subset 2 had the label Figure S2 ). Previous reports have shown changes in subsets of infiltrating T cells (Frederick et al., 2013) . A relative increase in CD3 T cells and cytotoxic CD8 + T cells was observed in tumors following therapy (P = 0.02 for both, Supporting information Table S3 ).
To establish a methodology to identify features of cell populations that escaped targeted therapy, Pre-Tx and Week 4 tumor cells from MP-059 were analyzed simultaneously in a new viSNE map (Figure 2a) . Features for viSNE analysis were selected based on a variance of 0.2 or greater across 14 melanoma tissue samples (Supporting information Table S2 ) following established methods (Irish et al., 2004 . Cells from this viSNE analysis were next characterized by MEM to quantify feature enrichment and phenotypic stability over time during treatment (Figure 2b ).
Analysis with viSNE and MEM indicated Pre-Tx cells were enriched
for neural crest stem cell markers Nestin, SOX10, SOX2, CD49F, and melanoma diagnostic biomarker S100β (Ordonez, 2014) . In contrast, Week 4 cells lost Nestin and CD49F expression and expressed other markers of neural crest identity including NGFR, SOX10, and SOX2.
Furthermore, Week 4 cells specifically lacked immune interaction protein MHC I (Figure 2c ) (Garcia-Lora, Algarra, & Garrido, 2003) . The overall change in tumor phenotype was calculated as change (Δ) in
MEM (ΔMEM) by subtracting Week 4 MEM enrichment scores from
those measure in the Pre-Tx sample (Diggins et al., 2018) . ΔMEM analysis revealed Nestin, a neural cell filament (Park et al., 2010) , and CD49F, a stem cell niche-associated integrin (Krebsbach & Villa-Diaz, 2017) , were the melanoma cell features whose enrichment changed the most from Pre-Tx to Week (Figure 3) . These results provided a quantitative workflow to characterize and track changes in tumor heterogeneity.
| Combined viSNE analysis of melanoma tumors identifies patient-specific changes in tumor phenotype following BRAF and MEK inhibitor treatment
To systematically identify subset phenotypes that escape therapy, matched tumors were placed into an analysis workflow that Table S4 ).
Cell subsets were categorized into three groups by comparing Pre-Tx and Week 4 subset abundance (Supporting information Figure S4 ). An intratumoral cell subset was considered to have regressed when >75% of its cells were observed Pre-Tx, meaning that it decreased in abundance by at least 50% on treatment. In contrast, a subset was considered to have emerged when >75% of its cells were seen at Week 4. All other subsets demonstrated less than 50%
change from Pre-Tx to Week 4 and were considered to have persisted (Supporting information Figure S4 ). Thus, the terms regressing, persisting, and emerging used here refer to changes in the abundance of cells within a single tumor and are not comparable to overall clinical assessments of patient responses to treatment. Once subsets were categorized, MEM was used to identify common phenotypic 
Abundance (%) signatures of each melanoma cell group. Compared to the other subsets, regressing melanoma cell subsets (Figure 3c, e.g., subsets 24, 27, 1, and 26) were enriched for neural crest stem cell proteins such as Nestin, CD49F, SOX2, and SOX10, melanocyte biomarker S100β, and immune interaction protein MHC I (Supporting information Table S4 and Supporting information Figure S4 ). In contrast, the emerging melanoma cell subsets especially lacked Nestin and CD49F (Supporting information Table S4 and Figure S4 ). The phenotypes of the persisting cells were more heterogeneous, and no proteins were especially enriched in these cells (e.g., Supporting information Figure   S4 , SOX2, SOX10, and CD49F). However, persisting cells contrasted with both regressing and emerging cell subsets, in that they most commonly lacked MHC class I protein expression (Supporting information Figure S4 and Table S4 ).
| Significant loss of Nestin protein expression was observed in melanoma cells at Week 4 following dabrafenib and trametinib
As the melanoma cell subsets with the greatest changes in abundance on treatment also shared similar phenotypes, median To investigate these results further, Kaplan-Meier statistical analysis was performed on 11 patient sets, which revealed no significant association between Nestin or CD49F expression and outcome (Supporting information Figure S8 ). Analysis of tumor size suggested that low expression of Nestin and CD49F might be more common in larger tumors (Supporting information Figure S9 ). Additional analysis of publicly available single-cell RNA-Seq data from therapy-naïve and relapse samples revealed increased Nestin transcript expression at the time of relapse in some samples (Supporting information Figure S10 ) (Tirosh et al., 2016) . Taken together with the protein measurements made at Week 4 here, these findings suggest that melanoma cells lacking Nestin protein after treatment may be capable of repopulating the Nestin-expressing melanoma cell population by the time of relapse. Figure S4 ) and with cells characterized at the time of relapse in other studies (Hugo et al., 2015; Tirosh et al., 2016) . Thus, while relapse is likely driven by diverse mechanisms among patients, the populations of cells initially involved in evading a single treatment may have common, targetable features.
While the selection of stemlike subsets has been implicated as the primary means of relapse in other cancers, cellular plasticity and therapy-induced reprogramming could be responsible for the shift in phenotype in melanoma (Holzel, Bovier, & Tuting, 2013) . Neural cell plasticity and therapy-induced reprogramming have previously been observed in models of melanoma, including the emergence of melanoma tumors that display a dependence on MAPK inhibition to support tumor growth (Das Thakur et al., 2013; Handoko et al., 2013; Sun et al., 2014) . IHC data published previously for tumors from patients on this trial showed a decrease in Ki67-positive cells to an average of 2.9% at Week 4 (Johnson et al., 2015) . This result indicates that proliferation is largely absent by Week 4 and suggests it is unlikely that the changes in tumor composition observed here can be explained solely by the growth of an intrinsically resistant subset. Furthermore, analysis of therapy-naïve and relapse samples suggests that the Pre-Tx cellular composition of the tumor recovers after the end of targeted therapy and prior to the time of relapse (Tirosh et al., 2016) .
While the increase in T-cell infiltration suggested a robust response to therapy, melanoma cells were not completely eradicated (Frederick et al., 2013) . Melanoma subsets observed after therapy were either emerging novel subsets not present before therapy or persisting MHC class I-negative cells. Lack of MHC class I expression has been implicated in impaired immune surveillance (Garcia-Lora et al., 2003) .
It was also apparent that individual melanoma cells almost never co-expressed Nestin and PD-L1 (N = 7 pairs, Supporting information Figure S5 ). At the sample level, low median PD-L1 expression was seen on some melanoma cell subsets (e.g., Subsets 1, 6, 11, Supporting information Figure S4 ). In these subsets of PD-L1-expressing melanoma cells, a deficit in Nestin protein expression was observed. Furthermore, in subsets where median Nestin expression was higher (e.g., subsets 27, 26, and 24), median PD-L1 expression was low to zero. Taken together, loss of Nestin might represent a transient identity influenced by therapy, and loss or a sustained lack of MHC proteins coupled with PD-L1 expression could facilitate evasion from the immune system to enable a broader range of genomic and nongenomic alterations to arise at relapse (Hugo et al., 2015; Johnson, Stuhlmiller, Angus, Zawistowski, & Graves, 2014) . Targeting 
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